8 April 2010 | Helen Gilbert
Australian biopharmaceuticals firm CSL is to introduce an ethical behaviour clause into its supplier contracts.
The company has more than 6,000 vendors worldwide and many provide materials and services that contribute to the development of life-saving therapies.
The clause was signalled in CSL's 2009 corporate responsibility report but the document did not provide details of what the clause would say.
The report also said the company’s new code of responsible business practice had been distributed to all major suppliers.
The code, which outlines the firm’s ethical standards, applies to contractors, suppliers and distributors. It includes a commitment to complying with local laws and regulations; guidance in making ethical decisions in situations of potential conflict of interest, political involvement and bribery; and a commitment to health and safety standards.
The report added that key and critical suppliers are managed through ongoing dialogue, formal performance reviews and quality audits.
“In 2008-09 we conducted 288 quality audits, 56 (or 25 per cent) more than the previous year,” it said. “We also require our critical suppliers to develop risk management plans to ensure security of supply, which has proven especially important for influenza pandemic preparedness.”